Warnex Inc.

Warnex Inc.

September 27, 2005 07:01 ET

Warnex launches new website: Prenatest.ca

LAVAL, QC, Sept. 27 - Warnex Inc. (TSX:WNX) announced today the
launch of its new website www.prenatest.ca for its Prenatest® prenatal
screening test available throughout the province of Quebec.

A Prenatest test performed during the first trimester of a pregnancy is
useful in determining a woman's risk of carrying a fetus affected by one of
the most common birth chromosomal anomalies: Down syndrome (trisomy 21) and
trisomy 18. Testing may also be adapted for women in their second trimester.

"The Prenatest screening test is the earliest and most effective Down
syndrome screening tool available in the first trimester," said Mark Busgang,
President and CEO of Warnex. "It is quick and straightforward and is designed
for pregnant women of all ages. It does not pose any danger to the mother or
the fetus. Early screening of chromosomal anomalies empowers women by giving
them the information they need to consider their options regarding further
diagnostic tests."

This new website is part of Warnex's new marketing program for the
Prenatest screening test, which also includes an extensive radio advertisement
campaign.

In addition to Prenatest prenatal screening, Warnex Clinical Services
offers specialized laboratory testing services in a wide range of clinical
specialties, including: allergy and immunology, cardiology, endocrinology,
gastroenterology, genetics, infectious diseases, obstetrics/gynecology, and
oncology.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
toxins, yeasts, and fungi, as well as meat speciation and bioterrorism.
Warnex's profitable and growing analytical, bioanalytical, and clinical
service groups offer a variety of quality control services, method development
and validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Prenatest is a registered trademark of Warnex Inc., Laval, Canada.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or
otherwise.

Contact Information